Will 2016 be a landmark year for COPD treatment?
London, UK – Dove Medical Press, publisher of International Journal of Chronic Obstructive Pulmonary Disease (IJCOPD), today announced the launch of Open Outlook: COPD, a year-long exploration of the horizon of COPD treatment. The program forms part of their 10th anniversary commemorations.
The program will take an in in-depth look at the impact of advances on COPD management and outline what this means for future research. Contributors will include IJCOPD Editor-in-Chief Dr Richard Russell, Lymington New Forest Hospital and University of Oxford, UK, Associate Editor, Professor David Mannino, University of Kentucky, USA and Professor Peter Barnes, Imperial College London, UK.
"The starting point for this program is to look at what the last 10 years have meant for our existing management of COPD. We'll then look at what's ahead in the next five, including COPD treatment guidelines, preclinical and clinical targets and the possibilities presented by Big Data," explained Dr Russell. "We expect significant advances in 2016, and we'll outline what that means for patient care."
The program will consist of a series of concise video perspectives, published sequentially on the IJCOPD journal webpage. The first video will be available from February 2016 at http://www.dovepress.com/ijcopdoo.t
About Dove Medical Press
Dove Medical Press Ltd is a privately held UK company specializing in the publication of Open Access peer-reviewed journals across the broad spectrum of science, technology and especially medicine. Dove Medical Press was founded with the objective of combining the highest editorial standards with the 'best of breed' new publishing technologies. Dove Medical Press launched their first journals in 2005.
Dove Medical Press is a member of OASPA, ALPSP, DOAJ, the Publisher's Association, HINARI and COPE.
About the International Journal of Chronic Obstructive Pulmonary Disorder (IJCOPD)
Launched in 2006, IJCOPD (Impact Factor: 3.141) is an international, peer-reviewed Open Access journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Directed at specialists and healthcare professionals. special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols.